George Hampton

George Hampton is the President and Chief Executive Officer of Currax Pharmaceuticals, an investor-owned pharmaceutical company dedicated to providing life-changing medicines to patients worldwide who are living with chronic, progressive diseases. Currax operates in more than 50 countries and serves millions of patients through Contrave®, its primary medicine indicated for chronic weight management in adults.

George believes that working in the pharmaceutical industry carries a profound obligation to patients—those who count on us to deliver on their hopes for improved health, well-being and quality of life.

A veteran pharmaceutical and biotechnology executive, Mr. Hampton brings more than 30 years of experience driving business growth through the launch of innovative medicines and the expansion of patient access to treatments addressing chronic conditions. His diverse background spans for-profit, non-profit, public and privately held organizations. He has led teams that introduced transformative therapies across rare diseases, autoimmune conditions, primary care, orthopedics, diabetes and cardiovascular medicine.

Before joining Currax, Mr. Hampton served as Executive Vice President of the Primary Care Business Unit at Horizon Pharmaceuticals (now Amgen), later leading the company’s Global Orphan Business Unit and International Operations. Earlier in his career, he held senior leadership roles at Amylin Pharmaceuticals, Abbott (now AbbVie) and G.D. Searle (now Pfizer), living and working in multiple international markets.

Since joining Currax in April 2019, George has focused on breaking down barriers to obesity care and ensuring that patients aren’t left waiting for the healthcare system to catch up. Under his leadership, Currax has made patient access a top priority—launching CurAccess™, a program designed to provide an affordable pathway to treatment for patients facing insurance gaps. Guided by his belief that science only matters when it reaches the people who need it, George continues to champion a patient-first approach to innovation and growth at Currax.

Mr. Hampton earned his Bachelor of Science degree from Miami University in Oxford, Ohio. He currently serves on the boards of Currax Pharmaceuticals, Gamida Cell (an oncology cell therapy company) and the Belmont University School of Medicine Advisory Board. His previous board service includes IMAC Holdings (NASDAQ: IMAC), Amryt Pharmaceuticals (now Chiesi Farmaceutici) and the Nashville Health Care Council.